



NIH AIDS Reagent Program
20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	CEF Control Peptide Pool
Catalog Number:	9808
Lot Number:	160010
Provided:	0.5 mg net each peptide (16 mg Net total).
Description:	This pool consists of peptides from influenza virus, cytomegalovirus, and Epstein-Barr virus. It serves as a positive control for CD8+ T cell activation.
Sequence:	See attached table. MHC class I restricted T cell epitopes from human cytomegalovirus, Epstein Barr virus and influenza virus.
Purity:	>90%
Analytical Test:	HPLC, mass spectrometry, amino acid sequencing and N-terminal sequencing were used to determine the sequence and purity. See attached table for estimated purity.
Solubility:	This peptide pool is soluble in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution. Please note: Recent unpublished reports indicate that Cys and Met containing peptide sequences are highly unstable when stored in DMSO for prolonged periods of time. Degradation of these peptides in DMSO can occur within days to weeks. Although a correlation between peptide decay and effect on biological activity is currently unknown, for prolonged peptide stability, we recommend freshly prepared working solutions from freeze dried aliquots of these and other peptide pools.
Special Characteristics:	A panel of 32 of 8–11 mer peptides representing epitopes recognized by CD8+ T cells and presented by 15 class I HLA-A and HLA-B alleles. This reagent is useful in applications such as ELISPOT, intracellular cytokine and CTL assays. See table below for a list of sequences and relevant HLA alleles included in this peptide pool.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

[Table of CEF Control Peptide Pool.](#)

[Data for the individual peptides.](#)

Recommended Storage:

Keep at -20°C lyophilized and -80°C after reconstitution.

Contributor:

DAIDS, NIAID.

References:

Currier, J. R., Kuta, E. G., Turk, E., Earhart, L. B., Loomis-Price, L., Janetzki, S., . . . Cox, J. H. (2002). A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. *J Immunol Methods*, 260(1-2), 157-172. [PUBMED](#)

Mwau, M., McMichael, A. J., & Hanke, T. (2002). Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. *AIDS Res Hum Retroviruses*, 18(9), 611-618. doi:10.1089/088922202760019301 [PUBMED](#)

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: CEF Control Peptide Pool from DAIDS, NIAID."

Last Updated:

November 14, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.